Immuron surges after U.S. PROIBS launch deal adds to recent strong FY26 update

Immuron Limited (IMRN) is up 60.4% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver is Immuron’s September 4, 2026 announcement that it signed an exclusive U.S. distribution agreement for PROIBS with Calmino group AB, giving investors a new commercial expansion story in digestive health. The rally also appears to be supported by momentum from the company’s August 28, 2026 preliminary FY26 results, which showed record sales, higher cash, and progress on key pipeline and partnering milestones. ([globenewswire.com](https://www.globenewswire.com/news-release/2026/09/04/3356450/37134/en/immuron-to-launch-proibs-in-the-united-states.html?utm_source=openai))

Details:

Immuron announced it will launch PROIBS in the United States under an exclusive distribution agreement, expanding a product it already introduced in Australia during FY26. ([globenewswire.com](https://www.globenewswire.com/news-release/2026/09/04/3356450/37134/en/immuron-to-launch-proibs-in-the-united-states.html?utm_source=openai))

The company described the U.S. digestive and gut health supplement market as a multibillion-dollar opportunity, which may have increased investor interest in the commercial upside of the deal. ([globenewswire.com](https://www.globenewswire.com/news-release/2026/09/04/3356450/37134/en/immuron-to-launch-proibs-in-the-united-states.html?utm_source=openai))

In its FY26 preliminary results released one week earlier, Immuron said record annual sales reached A$7.7 million, up 6% year over year, with U.S. sales also growing. ([nasdaq.com](https://www.nasdaq.com/press-release/immuron-reports-fy26-preliminary-results-2026-08-28))

That same FY26 update said cash increased to A$9.0 million and highlighted upcoming milestones including portfolio expansion and IMM-529 partnering progress, reinforcing a broader growth narrative around the stock. ([nasdaq.com](https://www.nasdaq.com/press-release/immuron-reports-fy26-preliminary-results-2026-08-28))

Sources:

Immuron Limited, SEC, Nasdaq

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$IMRN Hedge Fund Activity

We have seen 3 institutional investors add shares of $IMRN stock to their portfolio, and 8 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

CITADEL ADVISORS LLC removed 31,978 shares (-69.8%) from their portfolio in Q1 2026, for an estimated $24,776
MORGAN STANLEY removed 28,874 shares (-94.4%) from their portfolio in Q2 2026, for an estimated $30,606
JANE STREET GROUP, LLC removed 22,458 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $17,400
HRT FINANCIAL LP added 20,584 shares (+inf%) to their portfolio in Q2 2026, for an estimated $21,819
XTX TOPCO LTD removed 17,383 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $18,425
VIRTU FINANCIAL LLC removed 11,370 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $8,809
TWO SIGMA SECURITIES, LLC removed 10,906 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $11,560

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.